Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo #2 Clear all
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Light Therapy for Depression in Adolescent Outpatients

NCT05823090
View directory record Official record
Conditions
Depression, Adolescent - Emotional Problem
Interventions
light box (Carex DayLight Classic Model)
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

NCT00365859
View directory record Official record
Conditions
Autistic Disorder, Behavioral Symptoms
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
55
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Maintaining Abstinence in Chronic Cigarette Smokers - 1

NCT00087880
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion and NRT
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 25, 2026, 2:09 AM EDT
Recruiting Early Phase 1 Interventional

Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder

NCT06582888
View directory record Official record
Conditions
Nicotine Addiction, Craving
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 25, 2026, 2:09 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation

NCT05317676
View directory record Official record
Conditions
Tibial Fractures, Fibula Fracture, Knee Fracture
Interventions
Palmitoylethanolamide, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 25, 2026, 2:09 AM EDT
Recruiting Phase 2 Interventional

Ertugliflozin in Chronic Heart Failure

NCT04438213
View directory record Official record
Conditions
Heart Failure
Interventions
Ertugliflozin, Metolazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of SAMe in Patients With Alcoholic Liver Disease

NCT00573313
View directory record Official record
Conditions
Liver Disease, Alcoholic
Interventions
S-adenosylmethionine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

NCT01414920
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
80
States / cities
Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)

NCT01391182
View directory record Official record
Conditions
Degenerative Joint Disease, Osteoarthritis
Interventions
EACA, Placebo arm
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Long-Chain Polyunsaturated Fatty Acid Supplementation on Toddler Cognition

NCT00982462
View directory record Official record
Conditions
Infant Development
Interventions
Docosahexaenoic acid (DHA) and arachidonic acid (ARA), Corn oil placebo
Dietary Supplement
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
351 Days to 379 Days
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 25, 2026, 2:09 AM EDT
Not listed Phase 2 Interventional

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

NCT02335203
View directory record Official record
Conditions
Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia
Interventions
Depot medroxyprogesterone acetate, Placebo
Drug · Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Self-Administered Lidocaine Gel for Pain Management With IUD Insertion

NCT02738203
View directory record Official record
Conditions
IUD Insertion
Interventions
Vaginal 2% Lidocaine, Surgical Lubricant Jelly
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

NCT00227942
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Estrogen Replacement Therapy, Zolpidem, placebo
Drug
Lead sponsor
Hadine Joffe, MD
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Antidepressants in Chronic Back Pain

NCT00964886
View directory record Official record
Conditions
Back Pain
Interventions
cognitive behavioral therapy, desipramine hydrochloride, benztropine mesylate 0.125 mg daily
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

NCT03497442
View directory record Official record
Conditions
Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions
Brimonidine Tartrate, Placebo Vehicle Gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

NCT01454986
View directory record Official record
Conditions
Healthy
Interventions
ALXN1007, Placebo
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT00658086
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, normal saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 25, 2026, 2:09 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694
View directory record Official record
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
61
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494
View directory record Official record
Conditions
Moderate to Severe Acute Lower Back Pain
Interventions
SP-103, Placebo
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Fernandina Beach, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fiber Metabolism in Chronic Obstructive Pulmonary Disease

NCT04459156
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Aging
Interventions
Fiber Inulin, Placebo Maltodextrin
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 25, 2026, 2:09 AM EDT